Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-06-24

Clinical Trial Update: A Trial of Grazax in Subjects With Hayfever [Phase 3]

View source ↗

Summary

Phase 3 trial of Grazax for hay fever/allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GRAZAX (birch pollen sublingual immunotherapy tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergy | Phase 3 | Status: COMPLETED